Incyte Corporation (INCY)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS45337C1027
120.08 USD
-1.33% today Updated 13 Nov 2026 16:30
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Incyte Corporation, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:30. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Next results
09 Feb 2027
in 88 days · 08:00 · estimate 1.97
Last results
-3.60 vs -3.87 estimated
29 Oct 2026 · Beat +6.9%
Beat the estimate
6 of 12
6 missed · 0 in line · 3 beats in a row
Average surprise
-14.0%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 09 Feb 2027 08:00 | 1.97 | — | — | Upcoming |
| 29 Oct 2026 07:00 | -3.87 | -3.60 | +6.9% | Beat |
| 28 Jul 2026 07:00 | 2.15 | 3.09 | +44.0% | Beat |
| 28 Apr 2026 07:00 | 1.34 | 1.81 | +35.1% | Beat |
| 10 Feb 2026 07:00 | 1.92 | 1.80 | -6.1% | Miss |
| 28 Oct 2025 07:00 | 1.64 | 2.26 | +38.0% | Beat |
| 29 Jul 2025 07:00 | 1.47 | 1.57 | +6.6% | Beat |
| 29 Apr 2025 07:00 | 1.03 | 1.16 | +12.3% | Beat |
| 10 Feb 2025 07:00 | 1.55 | 1.43 | -8.0% | Miss |
| 29 Oct 2024 07:00 | 1.09 | 1.07 | -2.0% | Miss |
| 30 Jul 2024 07:00 | 1.11 | -1.82 | -264.5% | Miss |
| 30 Apr 2024 07:00 | 0.83 | 0.64 | -23.1% | Miss |
| 13 Feb 2024 07:00 | 1.15 | 1.06 | -7.7% | Miss |
| 31 Oct 2023 07:00 | 1.07 | 1.10 | +3.1% | Beat |
| 01 Aug 2023 07:00 | 0.87 | 0.99 | +14.5% | Beat |
| 02 May 2023 07:00 | 0.74 | 0.37 | -50.0% | Miss |
| 07 Feb 2023 07:00 | 0.57 | 0.62 | +8.1% | Beat |
| 01 Nov 2022 07:00 | 0.71 | 0.60 | -14.9% | Miss |
| 02 Aug 2022 07:00 | 0.75 | 1.01 | +35.5% | Beat |
| 03 May 2022 07:00 | 0.69 | 0.55 | -20.1% | Miss |
| 08 Feb 2022 07:00 | 0.87 | 0.10 | -88.5% | Miss |
| 02 Nov 2021 07:00 | 0.76 | 1.18 | +55.3% | Beat |
| 03 Aug 2021 07:00 | 0.74 | 0.80 | +8.1% | Beat |
| 04 May 2021 07:00 | 0.64 | 0.67 | +4.2% | Beat |
| 09 Feb 2021 07:00 | 0.77 | 0.93 | +21.4% | Beat |
| 05 Nov 2020 07:00 | 0.76 | 0.23 | -69.6% | Miss |
| 04 Aug 2020 07:00 | 0.86 | 1.24 | +43.7% | Beat |
| 05 May 2020 07:00 | -2.80 | -2.86 | -2.2% | Miss |
| 13 Feb 2020 07:00 | 0.58 | 0.65 | +12.8% | Beat |
| 29 Oct 2019 07:00 | 0.64 | 0.82 | +28.2% | Beat |
| 30 Jul 2019 07:00 | 0.50 | 0.75 | +50.9% | Beat |
| 30 Apr 2019 07:00 | 0.41 | 0.62 | +49.5% | Beat |
| 14 Feb 2019 07:00 | 0.49 | 0.40 | -17.8% | Miss |
| 30 Oct 2018 07:00 | 0.41 | 0.38 | -6.2% | Miss |
| 31 Jul 2018 07:00 | 0.22 | 0.26 | +19.6% | Beat |
| 01 May 2018 07:00 | 0.12 | -0.01 | -108.7% | Miss |
| 15 Feb 2018 07:00 | -0.33 | -0.71 | -117.5% | Miss |
| 31 Oct 2017 07:00 | 0.06 | 0.17 | +165.6% | Beat |
| 01 Aug 2017 07:00 | -0.04 | -0.06 | -71.4% | Miss |
| 04 May 2017 07:00 | -0.88 | -0.96 | -9.1% | Miss |
| 14 Feb 2017 07:00 | 0.14 | 0.05 | -65.3% | Miss |
| 01 Nov 2016 07:00 | 0.02 | 0.19 | +1,039.8% | Beat |
| 09 Aug 2016 07:00 | -0.03 | 0.18 | +686.5% | Beat |
| 09 May 2016 07:00 | 0.27 | 0.12 | -55.0% | Miss |
| 11 Feb 2016 07:00 | 0.17 | 0.29 | +65.5% | Beat |
| 03 Nov 2015 07:00 | -0.42 | -0.22 | +47.4% | Beat |
| 04 Aug 2015 07:00 | -0.09 | -0.10 | -6.7% | Miss |
| 30 Apr 2015 07:00 | -0.07 | -0.11 | -50.2% | Miss |
| 12 Feb 2015 07:00 | -0.16 | -0.22 | -41.0% | Miss |
| 30 Oct 2014 07:00 | -0.07 | 0.33 | +558.3% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 5.1B | +21.2% | 1.3B | 25.0% | 6.41 | +4,173.3% | 1.3B |
| 2024 | 4.2B | +14.8% | 32.6M | 0.8% | 0.15 | -94.3% | 235.2M |
| 2023 | 3.7B | +8.9% | 597.6M | 16.2% | 2.65 | +74.3% | 449M |
| 2022 | 3.4B | — | 340.7M | 10.0% | 1.52 | — | 892.1M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 119.02 | 123.96 | 115.00 | 120.08 | -0.26% | 14,499,325 | |
| Oct 2026 | 120.47 | 122.87 | 107.78 | 120.39 | -0.79% | 42,562,600 | |
| Sep 2026 | 124.61 | 130.00 | 119.97 | 121.35 | -1.52% | 32,297,900 | |
| Aug 2026 | 120.22 | 130.80 | 115.77 | 123.22 | +3.10% | 27,881,700 | |
| Jul 2026 | 114.70 | 132.60 | 110.56 | 119.52 | +5.43% | 42,449,700 | |
| Jun 2026 | 96.48 | 115.56 | 92.18 | 113.36 | +17.18% | 47,036,600 | |
| May 2026 | 95.26 | 103.01 | 94.10 | 96.74 | +1.54% | 25,437,600 | |
| Apr 2026 | 94.65 | 102.86 | 92.55 | 95.27 | +1.22% | 30,366,700 | |
| Mar 2026 | 99.94 | 101.00 | 89.25 | 94.12 | -7.06% | 36,879,100 | |
| Feb 2026 | 99.75 | 109.48 | 97.25 | 101.27 | +1.20% | 37,325,700 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030 (opens in a new tab) MarketBeat · 11 Nov 2026 13:12
- Natera and Incyte partner on Phase II colorectal cancer trial (opens in a new tab) Clinical Trials Arena · 11 Nov 2026 11:19
- Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript (opens in a new tab) SeekingAlpha · 10 Nov 2026 13:00
- Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer (opens in a new tab) 10 Nov 2026 12:00
- Natera Enters Into Clinical Collaboration Agreement With Incyte For New Phase II Study In Colorectal Cancer (opens in a new tab) Benzinga · 10 Nov 2026 08:10
- Leerink Partners Maintains Outperform on Incyte, Lowers Price Target to $150 (opens in a new tab) Benzinga · 05 Nov 2026 17:20
- $1000 Invested In Incyte 20 Years Ago Would Be Worth This Much Today (opens in a new tab) Benzinga · 05 Nov 2026 11:34
- Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026 (opens in a new tab) 04 Nov 2026 14:00
- Incyte to Present at Upcoming Investor Conferences (opens in a new tab) 04 Nov 2026 13:00
- Incyte To Present New Data On Its 30 Abstracts At American Society Of Hematology Annual Meeting (opens in a new tab) Benzinga · 04 Nov 2026 10:08
- Bernstein Maintains Market Perform on Incyte, Raises Price Target to $108 (opens in a new tab) Benzinga · 02 Nov 2026 14:42
- What Does Incyte (INCY) First Patient Dosing Mean For Its Colorectal Cancer Pipeline? (opens in a new tab) Simply Wall St. · 31 Oct 2026 22:09
- INCY Q3 deep dive: product diversification accelerates as R&D spending weighs on margins (opens in a new tab) StockStory · 31 Oct 2026 07:15
- Buy, Sell, or Hold? Today’s Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte. Intel, Reddit, Rivian Automotive, and More (opens in a new tab) 24/7 Wall St. · 30 Oct 2026 12:14
- Incyte Corporation Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 30 Oct 2026 01:35
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 121.70 USD
- Market cap
- 24.8B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow INCY and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.